Valanafusp Alpha

N/A

Report date: 2023/08/02 20:00:51

Base Information

Drug NameValanafusp Alpha

Drug Alias NameIgG-IDUA fusion proteinRecombinant human insulin receptor monoclonal antibody-fused alpha-L-iduronidaseValanafusp Alfa - ArmaGen TechnologiesIgG-alpha-L-iduronidase fusion proteinHIRMAb-IDUA +[8]

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionDermatan sulfate degraders

TargetsDermatan sulfate

Therapy Area/IndicationsMucopolysaccharidosis I

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesBrazil

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesArmagen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesArmagen Inc

Active IndicationsN/A

Inactive IndicationsMucopolysaccharidosis I

Other Information

ATC CodeN/A